Predict your next investment

Thousand Oaks Biopharmaceuticals company logo
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
tobiopharm.com

See what CB Insights has to offer

Founded Year

2017

Stage

Series C | Alive

Total Raised

$169.36M

Last Raised

$61.42M | 6 mos ago

About Thousand Oaks Biopharmaceuticals

Thousand Oaks Biopharmaceuticals is an integrated CMC organization which enables its partners to provide affordable and accessible biologics for patients worldwide. The company provides high quality raw material, consumables, novel equipment, technical services and consultation, integrated CDMO services including cell line development from DNA sequences, process, analytical and customized cell cultural medium development, early, late phase clinical material supply and commercial manufacturing, bioanalytical services and regulatory filings, to speed biologics development from bench through clinic to market.

Thousand Oaks Biopharmaceuticals Headquarter Location

Building B1, Dongtinghu Road No.100 Linjiang Town, Haimen

Nantong, Jiangsu,

China

+86 0513-68067603

Latest Thousand Oaks Biopharmaceuticals News

Greater China Digest: GL Ventures co-leads Thousand Oaks round; Taiwan’s Influenxio bags $2m

Mar 10, 2021

Source: National Cancer Institute/Unsplash March 10, 2021 Thousand Oaks Biopharmaceuticals has raised over 400 million yuan ($61 million) in its Series C round of financing co-led by China State-Owned Capital Venture Investment Fund and GL Ventures, while Taipei-based Influenxio has garnered $2 million from DCM Ventures. GL co-leads $61m funding in Thousand Oaks China’s Thousand Oaks Biopharmaceuticals, Inc has bagged over 400 million yuan ($61 million) in its Series C round of financing co-led by China State-Owned Capital Venture Investment Fund and Asia’s PE firm Hillhouse Capital’s venture unit GL Ventures. Alternative assets investment manager CDH Investments, China-US Green Fund, and Sany Group’s PE arm Sany Foundation have joined as new investors, while return backers namely CICC Capital, CITIC Securities’ investment arm Goldstone Fosun Group’s sub-fund re-upped in the round, per a company statement on Wednesday. Investment bank CEE Capital facilitated the transaction. In January this year, Thousand Oaks had tied-up with Korea’s WSG Group to set up a bioprocess solution JV  to speed up the Korean biopharma industry by supplying serum-free cell culture media. Before the latest round, Thousand Oaks had closed 450 million yuan ($69 million) Series B round funding from CICC Capital, GL Ventures, China Construction Bank’s CCB International and other investors in July 2020. Taiwan’s Influenxio bags $2m Influenxio, a Taipei-headquartered leading social marketing platform for small businesses, has secured $2 million in its pre-Series A funding led by DCM Ventures. The three-year-old Influenxio has so far raised over $3 million in funding. Influenxio plans to deploy the proceeds towards talent recruitment and product development. It will also support the revamp of its Japan-based platform and expand to overseas markets. Influenxio helps small-to-medium enterprises in Taiwan and Japan to conduct marketing campaigns for audience engagements. Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday REGISTER 2You have one free story left this month.You have 2 free stories left this month.This is your last free story of the month. Register to continue reading our free content. × We will never share your information with third parties. If you don’t already have an account click the button below to create your account. Join DealstreetAsia's premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. Singapore Reporter/s In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must. Following vacancies can be applied for (only in Singapore). Following vacancies can be applied for (only in Singapore). A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion. A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia. Singapore Reporter/s In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must. Following vacancies can be applied for (only in Singapore). Following vacancies can be applied for (only in Singapore). A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion. A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Thousand Oaks Biopharmaceuticals Patents

Thousand Oaks Biopharmaceuticals has filed 8 patents.

The 3 most popular patent topics include:

  • Cuttlefish
  • Goldfish breeds
  • Graphical projections
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/12/2018

6/15/2021

Graphical projections, House types, Cuttlefish, Goldfish breeds, House styles

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/12/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/15/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Graphical projections, House types, Cuttlefish, Goldfish breeds, House styles

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.